COLL
COLLEGIUM PHARMACEUTICAL, INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$22.77
+1.74%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$22.25
From 52W high−54.31%
Volume1.99M
Market cap$705.85M
P/E (TTM)14.9x
P/S (TTM)0.9x
Div yield—
Key dataSep 18, 2026
Open
$22.25
From 52W high
−54.31%
Volume
1.99M
Market cap
$705.85M
ValuationView details →
P/E (Fwd)
3.3x
EV/EBITDA
2.4x
P/E (TTM)
14.9x
RSI (14)
25.4
MomentumView details →
1D Return
+1.74%
YTD Return
−51.87%
SummaryUpdated Jun 1, 2026
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a specialty pharmaceutical company founded in 2002 and headquartered in Stoughton, Massachusetts. The company went public in May 2015 and has evolved from a development-stage company into a commercial-stage pharmaceutical business focused on pain management and neuropsychiatric disorders. Through strategic acquisitions, including the 2018 purchase of BioDelivery Sciences International and the 2024 acquisition of Ironshore Therapeutics, Collegium has built a diversified portfolio of branded prescription medications that address significant unmet medical needs in pain management and ADHD treatment.
Similar companies
Latest newsMore news →
Collegium Pharmaceutical entered into an accelerated share repurchase agreement with Jefferies LLC to repurchase $50 million of its common stock, part of a $150 million buyback program authorized in July 2025.38d agoCollegium Pharmaceutical reported second quarter 2026 financial results, with quarterly net revenues of $199.9 million, up 6% year-over-year.45d ago